Get in Touch
Get Started
Menu
Get in Touch
Get Started

Acting on Alzheimer's


There is currently no cure for Alzheimer’s disease, but many new treatments are being studied with great potential to treat the root causes of this devastating disease - down at the cellular level.

Silene Biotech does not provide medical advice or therapy. If you have questions or concerns about Alzheimer's disease or specific treatments, please consult your doctor.

Alzheimer's by the Numbers 

65

Every 65 seconds a person is diagnosed with Alzheimer's.

1 in 10

US adults over the age of 65 have been diagnosed with Alzheimer's.

2x

Women are diagnosed with Alzheimer's 2x more than men. 

Rfont_ALZ-stages_2x@2x-1

Stem Cells as a New Treatment for Alzheimer's Disease

By targeting the underlying causes, stem cell therapy has the potential to slow, stop or even reverse Alzheimer's disease altogether. As we become older, technologies such as these become even more important: research has shown that the risk of getting Alzheimer’s doubles every five years after age 65, and the risk increases by 50 percent after age 85.

2015

Human umbilical cord blood mesenchymal stem cells (Korea)

Phase I, Completed 2015

Stem cells were obtained from umbilical cords and injected into the brain during surgery. No adverse effects occurred and the cells were well tolerated. Additional studies are being conducted to see how well it works, but there is early evidence that the factors released by these cells have a protective effect on brain cells. Learn more.

2018

AstroStem (Biostar)

Phase I & II, On-going, Expected Completion 2018

Stem cells can also be derived from a patient’s own fat, with the advantage that the stem cells are your own. This means the body will not reject them and immunosuppression is not necessary. AstroStem is being tested in a few different diseases and has so far shown no adverse side effects in the first patients treated. This treatment is being studied both in the US and Korea. Learn more.

2019

Allogeneic mesenchymal stem cells (Longeveron)

Phase I, On-going, Expected Completion 2019

Allogeneic mesenchymal stem cells are collected from the bone marrow of healthy individuals and expanded for intravenous injection. These cells are being used in a Phase I trial to treat AD, with results expected next year. Promisingly, these cells have been shown to be safe and possibly effective in humans for treating age-associated frailty. Learn more.

2020

Ischemia-tolerant mesenchymal stem cells (Stemedica) 

Phase II, On-going, Expected Completion 2020

Mesenchymal stem cells can be obtained from bone marrow and are expanded in a lab under low oxygen conditions. These ischemia-tolerant mesenchymal stem cells (itMSCs) are currently being tested for various diseases and conditions, including Alzheimer’s. An ongoing Phase II trial began in 2016 to test if the intravenous delivery of the cells slows AD progression. Learn More

Still have questions?

We're here to answer any other questions you may have. Schedule at time to talk or just call or text us at 1-833-STEM-FRZ (1-833-783-6379)
Schedule a free call